Ozempic Prices Lowered After Trump Deal

Novo Nordisk cut direct-to-consumer prices for its weight-loss drug Wegovy and diabetes treatment Ozempic to $349 a month from $499 and is offering new cash-paying patients the two lowest doses for $199 a month for the first two months, while keeping the highest Ozempic 2 mg dose at $499; the move is pitched as improving affordability and directly challenges Eli Lilly’s Zepbound, which carries a $349 lowest-dose price. The pricing shift follows President Trump’s announced deal with both companies to lower Medicare and Medicaid prices (to $245 a month) and to offer cash-pay purchases via TrumpRx.gov at $350 a month with plans to reduce to $250 over two years, plus a $149 pill dose option and a $50 co-pay pathway for severe obesity starting mid-2026. Novo Nordisk’s stock was unchanged on the news and Eli Lilly dipped about 0.2%, underscoring growing competitive pricing pressure and potential implications for GLP-1 market access and manufacturer margins.

Analysis

Novo Nordisk announced a direct-to-consumer price cut for Wegovy and Ozempic, lowering the out-of-pocket monthly price to $349 from $499 and offering new cash-paying patients the two lowest doses for $199 per month for the first two months, while retaining the highest Ozempic 2 mg dose at $499; the move intentionally aligns the lowest-dose price with Eli Lilly’s Zepbound at $349. The change follows President Trump’s negotiated agreement with Novo Nordisk and Eli Lilly to reduce Medicare and Medicaid prices and to channel cash purchases through a new TrumpRx site, signaling coordinated industry response to political pressure.

Under the announced framework, Medicare prices for GLP-1 treatments will be reduced to $245 per month from prior advertised levels up to $1,350, cash-pay purchases via TrumpRx are set at $350 with plans to fall to $250 over two years, a $149 pill option is proposed, and a $50 co-pay path for severe obesity is targeted for mid-2026. Novo Nordisk framed the adjustment as improving affordability and access, explicitly citing payer and patient reach as the rationale.

Market reaction was muted: Novo Nordisk shares were unchanged while Eli Lilly dipped about 0.2%, highlighting investor focus on margin and competitive dynamics rather than immediate demand shocks. The price cuts increase near-term risk to average selling prices and manufacturer margins but could expand volume and payer access; critical monitoring items are dose-mix shifts, uptake via TrumpRx and Medicare timing, and any further competitive or regulatory moves that could set broader pricing precedent.

Key Decisions for Investors

• Maintain exposure to Novo Nordisk while monitoring quarterly margin disclosure and sales mix toward lower-priced doses, as volume uplift could offset some ASP pressure
• Consider trimming or underweighting Eli Lilly near term given the slightly negative market reaction and potential revenue dilution from price alignment, pending clearer uptake data
• Monitor TrumpRx rollout metrics, Medicare enrollment volumes and timing of the $50 co-pay pathway as leading indicators of demand and payer mix changes
• Implement downside protection on GLP-1 revenue exposure (e.g., hedges or options) if company guidance shows sustained margin compression
• Reassess positions when company-level sales data for lower-priced cohorts and formal margin guidance are reported, as those will materially change conviction